Contact Us | Print Page | Sign In | Register
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 10
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

Industry News for MS (INforMS)
Thursday, October 11, 2018
CMSC InforMS: TG Therapeutics, Inc. Announces Final Phase 2 MS Data Presentation at ECTRIMS »
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial   ECTRIMS data review conf...
Wednesday, September 5, 2018
CMSC INforMS: Researchers Identify New Subtype of Multiple Sclerosis »
Researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the disease and...
Wednesday, August 29, 2018
CMSC INforMS: MRI Tests May Help Doctors Predict MS Progression in Patients »
Researchers may have figured out how to use information from these imaging tests to determine what type of multiple sclero...
Thursday, August 9, 2018   (0 Comments - view/add)
CMSC INforMS: Researchers Have a New Theory About What May Cause Multiple Sclerosis »
When the following headline in the Australian newspaper the Herald Sun caught my eye recently, I was cautiously intrig...
Monday, July 30, 2018   (0 Comments - view/add)
CMSC INFORMS: FDA Accepts File for Cladribine Tablets as Potential Tx for Relapsing Forms of MS »
PDF   ROCKLAND, Mass., July 30, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Ger...
Wednesday, April 25, 2018
CMSC INforMS: NEW OCREVUS (OCRELIZUMAB) DATA DEMONSTRATE REDUCTIONS IN ACTIVITY & PROGRESSION IN RMS »
We are pleased to announce that  new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neur...
Friday, March 23, 2018   (0 Comments - view/add)
CMSC INforMS: Phase III data in The Lancet show Novartis outcomes in secondary progressive MS »
·   EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial t...
Monday, March 5, 2018
CMSC INforMS: Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review »
Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (dacliz...
Wednesday, January 3, 2018
CMSC INforMS: CVS/Aetna Combo a Formidable Pharma Rival When it Comes to Access »
Last month's unusual consolidation of healthcare provider CVS Health with insurance company Aetna spawned a new behemoth t...
Friday, December 8, 2017   (0 Comments - view/add)
CMSC INforMS: Press Release - CMSC Receives Interprofessional CE Joint Accreditation »
  CMSC Receives Interprofessional Continuing Education Joint Accreditation for the Healthcare Team...
Thursday, December 7, 2017
CMSC INforMS: Fruits and Vegetables May Help Reduce Symptoms of Multiple Sclerosis: Study »
Eating a healthy diet containing loads of fruits and vegetables along with whole grains may lower disability and reduce sy...
Wednesday, December 6, 2017
CMSC INforMS: Increased Epilepsy Risk Identified in Multiple Sclerosis »
A direct correlation exists between the presence and severity of multiple sclerosis (MS) and the risk for epilepsy, acco...
Monday, December 4, 2017
CMSC INforMS: National MS Society Endorses MS "NARCRMS" Data Registry »
NEW YORK, Dec. 4, 2017 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society is proud to announce its endorse...
Friday, December 1, 2017   (0 Comments - view/add)
CMSC INforMS: Mayo Clinic Develops Test to Distinguish Other Demyelinating Diseases from MS »
The Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from m...
Tuesday, November 21, 2017
CMSC INforMS: Patients Tell Their Stories in Consortium of Multiple Sclerosis Centers’ Online Videos »
Maryland special education teacher Ingrid Hanson says that since she was diagnosed with multiple sclerosis five years ago,...
Wednesday, September 13, 2017
CMSC INforMS: Cognitive Impairment Worse Among PPMS Than RRMS Patients, German Study Finds »
Patients with primary progressive multiple sclerosis ( PPMS ) have more severe cognitive impairment than those with relaps...
Friday, August 4, 2017
CMSC INforMS: Consortium Announces New MS Physician Assistant Special Interest Group »
The Consortium of Multiple Sclerosis Centers (CMSC) will form a new Physician Assistant Special Interest Group to provid...
Monday, July 17, 2017
CMSC INforMS: 5 Areas of Research That Could Change the Future of MS Treatment »
Multiple sclerosis is a disease that affects the nervous system, disrupting messages between the brain and the rest of the...
Sunday, July 16, 2017
CMSC INforMS: Breastfeeding linked to reduced risk of multiple sclerosis - Study »
New York : Mothers who breastfeed for at least 15 months over one or more pregnancies may be 53 per cent less likely to de...
Friday, July 14, 2017
CMSC INforMS: 12 Ways Amazon’s Alexa Can Help People With Multiple Sclerosis »
“Alexa” is Amazon’s talking service that acts as a virtual personal assistant. According to tomsguide.com, as part of the...
Tuesday, July 11, 2017
CMSC INforMS: OMRF Multiple Sclerosis Center wins top MS research award »
OKLAHOMA CITY — The Oklahoma Medical Research Foundation's Multiple Sclerosis Center of Excellence won the Labe Scheinber...
Friday, July 7, 2017
CMSC INforMS: Minocycline May Slow Progression From Clinically Isolated Syndrome to MS »
Minocycline, a broad-spectrum tetracycline antibiotic, reduces risk of conversion from clinically isolated syndrome (CIS)...
Monday, July 3, 2017
CMSC INforMS: Multiple sclerosis - Antioxidant may slow disease progression »
New research offers hope for patients with multiple sclerosis, after finding that a common over-the-counter antioxidant ma...
Wednesday, June 14, 2017
CMSC INforMS: Research Sheds Light on Who's Multiple Sclerosis Could Worsen »
A preliminary study by senior author Bianca Weinstock-Guttman, MD , has heightened researchers’ understanding about which...
Tuesday, June 13, 2017
CMSC INforMS: Sodium Intake And Its Association With Multiple Sclerosis Progression »
HealthDay News — There is no association between average 24-hour urine sodium levels and conversion from clinically isolat...
Saturday, June 10, 2017
CMSC INforMS: New Multiple Sclerosis drug, backed by 40 years of research, could halt disease »
A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS) is hold...
Thursday, June 8, 2017
CMSC INforMS: CMSC Revises Recommendations for Gadolinium Use in MRIs »
Editor’s note: Patient columnist Laura Kolaczkowski attended the 31st annual Consortium of Multiple Sclerosis Centers conf...
Thursday, June 8, 2017
CMSC INforMS: ‘MS from the Inside Out’ Uses Virtual Reality to Share What Life for Patients Is Like »
Virtual reality (VR) technology is most commonly associated with gaming and entertainment, but it’s expanding into a varie...
Friday, June 2, 2017   (0 Comments - view/add)
CMSC INforMS: #CMSC17 – Ocrevus, Progressive MS and Other Research Highlights »
The recent annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) brought researchers and healthcare prof...
Friday, June 2, 2017
CMSC INforMS: Acne Therapy Reduces Rate of Multiple Sclerosis Progression, Canadian Study Reports »
A common acne medicine called minocycline can reduce the rate of multiple sclerosis progression in patients who are at e...
Wednesday, May 31, 2017
CMSC INforMS: #CMSC17 – Caregivers of MS Patients Say the Disease Exhausts Physically & Emotionally »
Most people who care for multiple sclerosis (MS) patients are happy to be caregivers, but they admit that their own emotio...
Tuesday, May 30, 2017
CMSC INforMS: #CMSC17 – Ocrevus Lowers MS Relapse Rates Even Further in Extension Study »
Multiple sclerosis patients who benefited from Ocrevus ( ocrelizumab ) in two Phase 3 clinical trials continued to ben...
Tuesday, May 30, 2017
CMSC INforMS: #CMSC17 – Physical Activity Halts Depression in Young MS Patients, Canadian Study Show »
Young multiple sclerosis (MS) patients who engage in physical activity can relieve symptoms of depression , concludes a C...
Tuesday, May 30, 2017
CMSC INforMS: #CMSC17 – Celgene’s Investigational Therapy Ozanimod Safe, Effective in Treating RMS »
Long-term treatment for up to 12o weeks, with the investigational drug Ozanimod (RPC-1063), found to be effective and sa...
Tuesday, May 30, 2017
CMSC INforMS: #CMSC17 – Rituxan-treated MS Patients 3x More Likely to Have Improved Brain Scans »
Multiple sclerosis patients who start Rituxan ( rituximab ) treatment are three times more likely to have unchanged or imp...

Displaying page 1 of 10
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275

info@mscare.org